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Brain metastasis is a significant clinical problem, yet the mechanisms governing tumor
cell extravasation across the blood-brain barrier (BBB) and CNS colonization are unclear.
Astrocytes are increasingly implicated in the pathogenesis of brain metastasis but
in vitro work suggests both tumoricidal and tumor-promoting roles for astrocyte-derived
molecules. Also, the involvement of astrogliosis in primary brain tumor progression
is under much investigation. However, translation of in vitro findings into in vivo and
clinical settings has not been realized. Increasingly sophisticated resources, such as
transgenic models and imaging technologies aimed at astrocyte-specific markers, will
enable better characterization of astrocyte function in CNS tumors. Techniques such as
bioluminescence and in vivo fluorescent cell labeling have potential for understanding the
real-time responses of astrocytes to tumor burden. Transgenic models targeting signaling
pathways involved in the astrocytic response also hold great promise, allowing translation
of in vitro mechanistic findings into pre-clinical models. The challenging nature of in vivo
CNS work has slowed progress in this area. Nonetheless, there has been a surge of
interest in generating pre-clinical models, yielding insights into cell extravasation across
the BBB, as well as immune cell recruitment to the parenchyma. While the function
of astrocytes in the tumor microenvironment is still unknown, the relationship between
astrogliosis and tumor growth is evident. Here, we review the role of astrogliosis in both
primary and secondary brain tumors and outline the potential for the use of novel imaging
modalities in research and clinical settings. These imaging approaches have the potential
to enhance our understanding of the local host response to tumor progression in the brain,
as well as providing new, more sensitive diagnostic imaging methods.
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Metastasis, the spread of cancer from the primary tumor site to
distant organs, is the leading cause of cancer morbidity and mor-
tality and 10–40% of all cancer patients will develop metastatic
spread to the brain (Nussbaum et al., 1996). However, our under-
standing of brain metastasis is still incomplete, and the unique
microenvironment of the CNS, both on a cellular and metabolic
basis, means mechanistic insights from peripheral organs cannot
be readily translated. The processes underlying the extravasation
of neoplastic cells across the blood-brain barrier (BBB), their sub-
sequent colonization of the perivascular space (Carbonell et al.,
2009) and later the parenchyma, are yet to be fully characterized.
Progress in this area is limited by the lack of robust in vitro assays
that truly reflect the complex nature of the CNS. It is necessary,
therefore, to develop better pre-clinical models, in tandem with
sophisticated imaging modalities, to better allow the investigation
of the pathogenic mechanisms underlying metastasis progression.
In turn, imaging may identify novel biomarkers for early tumor
detection and new therapeutic avenues.
Astrocytes are the most abundant member of the glial fam-
ily and have multiple roles in the central nervous system. As
well as providing structural support for neurons and the BBB,
as outlined below, they play an integral role in maintaining CNS
function, participating in synaptic activity, mediating ionic and
transmitter homeostasis, and regulating blood flow. At the same
time, astrocytes actively respond to challenges such as infec-
tion, injury, ischemia, and neurodegeneration, by changing their
transcriptional profile and morphology in the process of reac-
tive astrogliosis, which has been extensively reviewed (Pekny and
Nilsson, 2005; Sofroniew, 2009; Middeldorp and Hol, 2011) and
is characterized by up-regulation of glial fibrillary acidic protein
(GFAP).
This review aims to detail the role of astrocytes in both primary
and secondary CNS tumors, as determined from both in vitro
studies and in vivo pre-clinical models. Secondly, novel imaging
techniques, many of which have been successfully used in other
neuropathologies, will be discussed in the context of investigat-
ing astrogliosis in CNS tumors, both in vivo and potentially in the
clinic.
PRE-CLINICAL MODELS; MECHANISTIC INSIGHTS INTO THE
ROLE OF ASTROCYTES IN CNS TUMORS
PRIMARY BRAIN TUMORS
Besides the malignant astrocytes that comprise many primary
brain tumor sub-types, a role for stromal astrocytes in tumor
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progression has been constructed through human biopsy sam-
ples, co-culture in vitro experiments and transgenic in vivo mod-
els. Broadly speaking, two main forms of malignant brain tumor
exist, as classified according to cellular origin; oligodendrocy-
tomas, comprised of oligodendrocytes, and astrocytic neoplasms,
also known as gliomas, which can be further stratified into diffuse
astrocytoma, anaplastic astrocytoma, and glioblastoma multi-
forme (GBM) (Louis et al., 2007). GBM consists of neoplastic
astrocytes that are poorly differentiated, and is characterized by
high invasive potential and angiogenesis. It is the most commonly
diagnosed and aggressive glioma in adults and, hence, will be the
focus of work described here.
Immunohistochemistry reveals reactive astrocytes surround-
ing glioma in both human biopsies (Nagashima et al., 2002) and
murine models, as shown in Figure 1, and have been proposed
to have pro-immunogenic roles. For instance, glioma associated
astrocytes have a markedly different mRNA expression profile
to normal astrocytes, primarily displaying components of the
antigen presentation pathway, such as MHC Class II proteins
(Katz et al., 2012). This observation suggests that astrocytes inter-
act with “helper” T cells, leading to localized inflammation.
Astrocytes surrounding human glioma biopsies secrete CCL2,
a macrophage and T cell recruiting chemokine, with a strong
positive correlation between CCL2 expression and T cell infil-
tration (Carrillo-De Sauvage et al., 2012). However, as with all
aspects of the immune response to tumor growth, it does not
necessarily follow that the presence of T cells leads to tumor
cell clearance. Indeed, Barcia et al. demonstrate that although
T cells infiltrate the GBM microenvironment, very few cyto-
toxic T cells (CTLs) make immunological synapses with tumor
cells, whilst there is a greater population of potential regu-
latory T cells (Barcia et al., 2009), which attenuate immune
responses.
Further evidence that this interaction downregulates immune
function comes from co-culture experiments. Co-culture of either
GBM astrocytes or normal human astrocytes with T cells, leads
to a downregulation of IFN-γ production (Kostianovsky et al.,
2008), hence inhibiting effector function. Additionally, astrocytes
have been shown to directly induce T cell apoptosis via cell-cell
contacts; astrocytoma derived astrocytes express Fas ligand (FasL)
which interacts with Fas expressing cells, such as T cells, to induce
cytolysis (Saas et al., 1997). This mechanism is not restricted
to malignant astrocytes, but has been demonstrated in normal
astrocytes (Bechmann et al., 1999, 2002), suggesting that astro-
cytes in the glioma periphery could also be involved in repressing
anti-tumor immune function.
Interactions with microglia, as well as infiltrating monocytes,
also indicate that astrocytes could play a role in modulating
immune function in the tumor periphery. Both GBM derived
malignant astrocytes and normal human astrocytes suppressed
TNF secretion by microglia and monocytes, and also inhib-
ited the ability of these cell types to activate T cells owing to
downregulation of co-stimulatory molecules (Kostianovsky et al.,
2008).
FIGURE 1 | Astrocyte activation, as determined by GFAP staining, is
present in the peri-tumoral area of both primary (A) and secondary
(B) tumors. (A) (i) In a mouse model of glioma, the growth of DBRTG
glioma cells can be seen in green (GFP labeled), adjacent to a wall of
astrocyte activation, seen in red (Alexa555 probe) (ii). The merged image
(iii) indicates little infiltration of activated astrocytes into the tumor mass,
as quantified by arbitrary fluorescence units of GFAP activity (C). Figure
adapted from Lee et al. (2011). (B) In a mouse model of lung derived
brain metastasis, in which HARA-B cells were inoculated intra-cardially,
astrocyte activation (Cy3 probe, red) was observed surrounding
metastatic growth (Alexa488 probegreen). As with the glioma model,
astrocytes are present in the tumor periphery, rather than the core. The
extent of astrocyte activation increased with tumor size (D). Figure
adapted from Seike et al. (2011).
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Interleukin-1β (IL-1β) has been identified in reactive astro-
cytes in the glioma periphery, suggesting an anti-tumor immune
response (Nagashima et al., 2002). Conversely, in vitro, IL-1β
has been implicated in inducing glioma invasion (Bryan et al.,
2008; Huang et al., 2009), as well as promoting tumor growth
via autocrine induction of TNF signaling (Chung and Benveniste,
1990; Adachi et al., 1992). Other astrocyte-derived cytokines,
such as stromal derived factor-1(SDF-1), have also been identi-
fied in vitro as enhancing glioma growth (Barbero et al., 2003) and
invasiveness (Zhang et al., 2005). Furthermore, this invasive phe-
notype has been demonstrated in vivo using a transgenic mouse
model in which glioma is induced by platelet derived growth
factor (PDGF) over-expression. In this study, stromal astrocytes
in the peri-tumoral region were shown to express elevated lev-
els of Tenascin-C (TN-C) (Katz et al., 2012), an extra-cellular
matrix glycoprotein, previously shown to promote GBM invasion
(Sarkar et al., 2006).
Matrix metalloproteinases (MMPs) have been proposed to
play a key role in mediating glioma invasion through the
parenchyma, and peri-tumoral reactive astrocytes have been
shown, immunohistochemically, to express MMP2 in post-
mortem samples (Nagashima et al., 2002). At the same time,
in vitro co-culture experiments between human fetal astro-
cytes and human glioma cell lines (U251N and U87), indicate
that soluble factors released by glioma cells cleave the MMP2
pro-enzyme to its active form (Le et al., 2003), demonstrat-
ing the dynamic interaction between GBM and the stroma.
Angiogenesis is another key feature of GBM, and vascular
endothelial growth factor (VEGF), a mediator of de novo ves-
sel formation in glioma (Plate et al., 1993), has been observed
in reactive stromal astrocytes (Nagashima et al., 1999, 2002).
These findings suggest another route by which astrocytes drive
tumorigenicity.
SECONDARY BRAIN TUMORS
As mentioned, the dissemination of cancer cells from primary
tumors to the brain is a common end-point for cancer patients
with metastatic disease and is associated with poor progno-
sis. Most frequently, metastatic cells that colonize the CNS are
derived from lung tumors, followed by melanoma, breast and
renal malignancies (Barnholtz-Sloan et al., 2004). The molecu-
lar mechanisms governing such pathologies are beyond the scope
of this article, and are yet to be fully characterized, although
specific gene signatures have been shown to be predictive of
brain metastasis (Bos et al., 2009; Harrell et al., 2012; Lee et al.,
2012). To understand the complexities of the brain metastatic
process, and the involvement of astrocytes, we must first consider
the BBB.
The BBB serves as both a physical and metabolic barrier,
separating the interstitial fluid of the brain parenchyma from
peripheral blood flow, and is critical for maintenance of the neu-
ral environment in the CNS. It is comprised of multiple cell types,
but is primarily regulated by the endothelium and astrocytes,
with specialized tight junctions between endothelial cells serv-
ing to exclude metabolites. The unique composition of the BBB
also serves as an obstacle to circulating cancer cell extravasa-
tion. Colonization of the brain parenchyma is not just reliant
on traversing the endothelium, but also the glia limitans, the
layer of astrocytic endfoot processes that provide structural and
metabolic support to the endothelium.
Astrocytes contribute not just to BBB structure, by contact-
ing the vascular endothelium, but also to its genesis, inducing
tight junction formation between endothelial cells (Goldstein,
1988), and up-regulating expression of transporters such as the
brain specific glucose transporter, GLUT1 (Boado and Pardridge,
1990; McAllister et al., 2001). Astrocytes also subserve a metabolic
barrier function, for instance, inducing expression of endothe-
lial cell enzymes such as manganese superoxide dismutase, the
inducible metabolizer of oxygen free radicals (Schroeter et al.,
2001). Calcium signaling between the endothelium and astrocytes
(Leybaert et al., 1998; Braet et al., 2001) suggests that endothe-
lial changes may also have a dynamic effect on astrocyte function.
Hence, one could hypothesize that astrocytes will be activated as
early as the initial steps of adhesion of metastasizing cells to the
vascular endothelium.
Sophisticated imaging of fluorescent metastatic cells, using
multi-photon laser scanning microscopy (MPLSM), has allowed
the stages of brain metastasis to be visualized in vivo (Kienast
et al., 2010). The tortuous nature of the cerebral micro-
vasculature enforces a reduction in the speed of circulating cells
and arrest at vascular branch points is observed. Such arrested
cells can reside on the luminal side of the brain endothelium
for up to 5 days, in contrast to elsewhere in the body where
metastasizing cells rapidly extravasate within 24 h (Lorger and
Felding-Habermann, 2010). Using MPLSM, extravasation into
the perivascular space appeared to occur via active transmi-
gration through mechanically induced pores in the endothe-
lial membrane, as previously hypothesized (Kawaguchi et al.,
1982). In addition, it was demonstrated that growth within the
perivascular space is dependent on contact with the ablumi-
nal endothelial membrane (Carbonell et al., 2009), as has also
been demonstrated in glioma (Winkler et al., 2009). Only upon
growth of macrometastases, will the glia limitans be breached,
allowing spread of metastases into the parenchyma (Saito et al.,
2007).
The characteristic response of astrocytes to injury, seen in
numerous neuropathologies, including glioma, has also been
identified as a feature of the brain metastatic microenviron-
ment. A wall of reactive astrocytes has been reported around
haematogenous brain metastases in human post mortem tis-
sue (Zhang and Olsson, 1995; He et al., 2006), and recently
there has been great interest in establishing murine mouse mod-
els of brain metastasis to determine astrocyte reactivity in vivo
(Mendes et al., 2005, 2007; Fitzgerald et al., 2008; Lorger and
Felding-Habermann, 2010; Seike et al., 2011), as demonstrated
in Figure 1. Astrocytic responses have been demonstrated in
BALB/c mice in response to both the syngeneic 4T1 mammary
carcinoma cell line, as well as in SCID mice in the response
to the human MDA-MB-435 cell line, as early as 3 days post
metastatic induction via intra-carotid inoculation (Lorger and
Felding-Habermann, 2010). Astrocyte reactivity was induced
whilst MDA-MB-435 cells were still intra-vascular, in contact
with the luminal endothelial membrane, and continued through-
out extravasation and growth over a 50 days time course.
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Likewise, Mendes et al. utilized a mammary carcinoma cell line,
ENU1564, injected intra-cardially, to demonstrate astrogliosis
in response to brain metastases in a rat model (Mendes et al.,
2007).
Gliosis is not only found in response to metastases of mam-
mary origin; Izraely et al. demonstrated astrocyte activation in
nude mice in response to metastatic melanoma (Izraely et al.,
2012) and Seike et al. demonstrated a wall of astrogliosis in nude
mice in response to the human lung cancer cell, HARA-B. In
this study, a positive correlation was found between tumor size
and the extent of astrocyte activation and, interestingly, astro-
cyte activation was more robust in hippocampal metastases as
compared to cortical metastases (Seike et al., 2011). Such dif-
ferential astrocytic responses have also been observed in other
disease models, such as intracerebral lipopolysaccharide (LPS)
challenge (Espinosa-Oliva et al., 2011). These differential reac-
tions may reflect the regional heterogeneity of astrocytes, both in
terms of astrocytic density (which is greater in the hippocampus
than the cortex), proliferation rates (which are higher in the hip-
pocampal dentate gyrus than the cortex) (Emsley and Macklis,
2006) and molecular signature with regards to immune func-
tion. In vitro, hippocampal astrocytes have been shown to express
higher levels of MHC Class II protein, Il-6 and ICAM-1 compared
to cortical astrocytes, as well as displaying increased nitric oxide
(NO) production (Morga et al., 1998), all of which one would
hypothesize to modulate astrocyte response to metastatic growth.
Indeed, studies of metastatic distribution in human patients, sug-
gest that the hippocampus is a rare locale for tumor growth,
as compared to the cerebellum or frontal lobe (Delattre et al.,
1988; Ghia et al., 2007; Bender and Tome, 2011). Potentially, the
more robust responses of astrocytes in the hippocampus, both
on a cellular and immunological basis, could hamper metastatic
growth.
As in glioma, the “double edged sword” of inflammation
that is so often reviewed in the literature, not just in can-
cer (Hagemann et al., 2007; Lin, 2010; Rizzo et al., 2011) but
in other diseases such as asthma (Balhara and Gounni, 2012),
stroke (Doyle and Buckwalter, 2012), and neurodegeneration
(Wyss-Coray and Mucke, 2002), appears to also be a feature
of the astrocytic response to brain metastasis. In vitro studies
have shown that astrocytes produce NO, via inducible nitric
oxide synthase (Simmons and Murphy, 1992), and that this has
tumoricidal effects in both primary and secondary cancer cell
lines (Samdani et al., 2004). Evidence that NO induces GFAP
upregulation (Brahmachari et al., 2006) suggests that this may
result in increased detection of reactive astrocytes with disease
progression.
However, a greater burden of evidence suggests a tumor pro-
moting role for astrocytes. Immunohistochemical analysis of
human biopsies has demonstrated up-regulation of endothelin
[a cancer cell mitogen (Bagnato et al., 1997)] expression by
tumor associated astrocytes (Zhang and Olsson, 1995). Moreover,
co-culture experiments between astrocytes and various tumor
cell lines indicate that astrocytes release soluble factors that can
enhance tumor cell growth. For instance, endothelin-1, besides
its role in vasoconstriction, has also been proposed to be mito-
genic (Kasuya et al., 1994; Bagnato et al., 1997, 2002), and analysis
of biopsy samples suggests that endothelin-1 is expressed by
astrocytes in 85% of patient cases (Zhang and Olsson, 1995).
Additionally, the receptor for endothelin-1, ETB, is upregulated
in a brain-metastatic melanoma cell line over 3 fold, as compared
to a non-metastatic cell line (Boukerche et al., 2004). This find-
ing suggests that astrocytes may drive the molecular determinants
of metastatic potential. Furthermore, incubation of the lung ade-
nocarcinoma cell line PC14-PE6 with an immortalized astrocytic
cell line induced cancer cell ERK1/2 phosphorylation (Langley
et al., 2009), part of the MAP kinase signaling pathway heav-
ily implicated in tumor progression. ERK1/2 phosphorylation
has also been demonstrated in a metastatic mammary carcinoma
cell line, ENU1564, in response to astrocyte conditioned media
(Mendes et al., 2007). In this case, ERK1/2 activation was shown
to increase tumor cell invasiveness in vitro via induction of MMP2
expression, as was seen in astrocyte-glioma co-culture models
(Le et al., 2003).
Metastatic invasion may also be facilitated by astrocyte-derived
heparanase, which degrades heparin sulphate proteoglycans, a
major component of the extracellular matrix. Astrocyte hep-
aranase expression has been demonstrated in the peri-infarct
regions of in vivo stroke models (Takahashi et al., 2007; Li
et al., 2012a) and in rat astrocyte-tumor cell culture models.
In the latter case, it was shown that co-culture of astrocytes
with brain-metastatic melanoma cell lines led to a super-additive
increase in enzyme activity, potentially through neurotrophin sig-
naling (Marchetti et al., 2000). Treatment of melanoma cell lines
with astrocyte conditioned media led to increased cell invasion,
an effect which was abrogated with antibody-mediated neutral-
ization of heparanase. Further co-culture experiments between
astrocytes and several lung cancer derived cell lines indicate that
astrocytes secrete IL-6, TNF, and IL-1β, which stimulate tumor
cell growth (Seike et al., 2011). It has also been suggested that
astrocytes increase the anchorage-independent growth of cancer
cell lines and that this correlates with metastatic ability in vivo
(Fitzgerald et al., 2008), although the mechanism has yet to be
identified.
Astrocytes have also been shown to induce transcriptional
changes in co-cultured tumor cells that reflect the transcriptional
changes seen in vivo (Park et al., 2011). Here, a Competitive
Hybridization of Microarray Experiment (CHME) was used to
tease apart genes upregulated in metastases as compared to the
tumor micro-environment. In this case, human cancer cells were
introduced into immuno-compromised mice, and differing gene
signatures and methylation statuses between the cell populations
were demonstrated. Subsequently, astrocytes were cultured with
a breast carcinoma cell line, MDA-MB-231, and were shown to
induce a similar genomic signature in the tumor cells to that seen
in vivo, suggesting that astrocytes are mediators of tumor cell
transcriptional reprogramming. For instance, brain metastatic
cells were shown to upregulate genes involved in neuronal pro-
cesses such as glutamate receptor signaling, axonal guidance, and
neurotransmission. This novel approach to probing astrocytic
function in brain metastasis demonstrates the key role astro-
cytes play in tumor progression, but also highlights the need
to determine both the mechanism and the growth advantage
conferred.
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On balance, the studies detailed above suggest a pro-
tumorigenic role for astrocytes, however, further in vivo studies
are required to elucidate this. Besides these proposed roles in
tumor pathogenesis, astrocytes have also been implicated in pro-
tecting tumor cells from chemotherapeutic agents. Co-culture
of astrocytes with breast and lung cancer cell lines (MDA-MB-
231 and PC14Br4, respectively) leads to up-regulation of survival
genes such as BCL2L1, an anti-apoptotic member of the BCL-2
protein family (Kim et al., 2011). Such genes confer resistance to
a range of chemotherapeutics, and are absent in cell lines at sec-
ondary sites other than the brain, highlighting a novel role for
astrocytes. Further work has shown that the mechanism of cell
protection is cell contact dependent and mediated via gap junc-
tion facilitated sequestration of calcium from tumor cells (Lin
et al., 2010).
IMAGING ASTROCYTES in vivo
The advent of molecular imaging, both as a stand-alone modal-
ity and combined with transgenic mouse models, has enabled
the dynamic responses of astrocytes in numerous CNS patholo-
gies to be visualized. Such techniques, in addition to yielding
mechanistic insights, have potential for diagnostic imaging of
neuroinflammation. In vivo research into the role of astrocytes
in the tumor microenvironment is still in its infancy; however,
using the numerous methodologies outlined below, there is much
potential for better understanding the contribution of this most
abundant CNS cell type to the pathogenesis of primary tumors
and metastases.
In vivo LABELING OF ASTROCYTES
Astrocytes are primarily identified, in vitro, in vivo, and ex vivo,
by their specific expression of GFAP, a cytoskeletal protein upreg-
ulated in astrogliosis, via antibody mediated detection meth-
ods, or transgenic systems, as outlined below. Alternatively,
the propensity of astrocytes to specifically take up dyes such
as sulforhodamine 101 (SR101), and facilitate their spread via
gap-junctions (Nimmerjahn et al., 2004; Appaix et al., 2012),
has enabled the study of astrocytic function, predominantly in
slice models. Recently, such studies have been translated into
the in vivo setting, with SR101 applied to the exposed cor-
tex or injected intraperitoneally, immediately prior to imaging
(Nimmerjahn and Helmchen, 2012). Using this technique, the
intimate relationship between astrocytes and the endothelium
in healthy tissue has been demonstrated, with gap-junction sig-
naling between the two populations proposed (McCaslin et al.,
2011).
Dyes, however, only enable transient labeling over a matter
of hours and, therefore, techniques that allow long-term visu-
alization are more useful for studying astrocytes in pathology.
Viral vectors can be used to transfect cell types with fluores-
cent dyes. For example, a recombinant adenovirus-associated
vector (AAV) has been used to stably and chronically trans-
duce neurons and astrocytes, inducing green fluorescent protein
(GFP) expression and allowing in vivo two photon microscopy
of the visual cortex via cranial windows (Lowery et al., 2009).
Additionally, BBB permeable, GFP-labeled anti-GFAP antibodies
have very recently been used to image astrocytes, both in vivo and
ex vivo (Li et al., 2012b). The potential for longitudinal imag-
ing of astrogliosis by these means in response to CNS disease or
injury will enable the temporal and spatial profile of reactivity to
be mapped.
Transgenic models offer an even more stable approach. The
specific expression of GFAP by astrocytes allows its promoter to
be manipulated to drive the expression of reporter genes solely
in astrocytes, as first described in a transgenic mouse model
in which bacterial LacZ was placed under the GFAP promoter
(Brenner et al., 1994). Since then, transgenic models have been
engineered in which astrocytes express GFP (Zhuo et al., 1997;
Nolte et al., 2001), allowing for the observation of astrogliosis
in brain slices with fluorescent microscopy, and real-time in vivo
detection of astrogliosis using multi-photon microscopy. This
technique has been employed by several groups investigating sys-
tems such as retinal gliosis in diabetes (Kumar and Zhuo, 2010),
retinal neurotoxicity (Ho et al., 2009) and NMDA-induced astro-
cyte activation (Serrano et al., 2008). This transgenic model can
also facilitate sorting of astrocytes from surrounding brain tissue,
allowing mRNA expression profiling in glioma (Katz et al., 2012),
as described above.
Bioluminescence is another technique that allows visualiza-
tion of reactive astrocytes in vivo, by placing the luciferase gene
under the control of the GFAP promoter, as first described
by Zhu et al. (2004). This transgenic mouse line has enabled
astrocyte activation, in response to both glioma and metastatic
cell lines implanted directly into the brain, to be studied
dynamically and non-invasively (Lee et al., 2011). Using this
approach, Lee et al. showed that astrogliosis peaks 3 days
after tumor implantation and showed a biphasic time course
over a 28 days experimental period in both glioma and
metastatic models. An extended astrocyte response to brain
metastasis has also been observed in other groups (Lorger
and Felding-Habermann, 2010; Seike et al., 2011), includ-
ing our own (unpublished observations), using conventional
immunohistochemistry.
It is evident that labeling of astrocytes is highly dependent
on GFAP. It should be noted however that not all astrocytes
express detectable levels of GFAP and its expression in disease
states can be variable (Wang and Walz, 2003). S100β, a cal-
cium binding protein (Baudier et al., 1986), is often used as a
astrocyte marker, however there is cross-reactivity with oligoden-
drocytes (Deloulme et al., 2004; Hachem et al., 2005). In addition,
a number of other proteins are selectively expressed by astro-
cytes, such as the enzyme glutamine synthetase and aquaporin-4,
but their sub-cellular distribution renders them impractical for
astrocyte labeling (Yang et al., 2011). One should also note the
differential expression of astrocytic markers throughout develop-
ment. For instance, the glutamate transporter GLT-1 has been
shown, in vitro, to be expressed at high levels in astrocyte cul-
tures from embryonic stages, but not post-natal time points,
whereas the glutamate transporter GLAST is highly expressed
in astrocytes cultured from early post-natal time points, with
a decline seen from p10 (Stanimirovic et al., 1999). In vivo,
the spatial expression of these two transporters appears to
change during post-natal development (Voutsinos-Porche et al.,
2003).
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Rather than pursuing global markers for astrocyte identifi-
cation, attempts to identify markers for different phenotypes
of astrocyte reactivity would allow greater understanding of
the functional impact of gliosis at different spatial and tem-
poral locales. For instance, the cytoskeletal protein vimentin,
can be used to define astrocytes proximal to ischemic lesions,
where neuronal damage is present, but is absent in distal gliosis
(Petito et al., 1990; Wang and Walz, 2003). A recent compre-
hensive transcriptional profile of astrocytes in response to two
different in vivo challenges in mice, LPS and middle cerebral
artery occlusion (MCAO), demonstrates differential molecu-
lar profiles in response to the nature of the insult and time
from lesion induction (Zamanian et al., 2012). For example,
nestin and tenascin-C expression were observed in the astrocyte
response to stroke, but not LPS-induced inflammation. Studies
such as these demonstrate the considerable heterogeneity in astro-
cytic phenotypes, within and between disease states, and high-
light the need for imaging agents that reflect this diversity of
responses.
FUNCTIONAL IMAGING
Astrocyte reactivity is just one facet of the contribution of glia
to the healthy and diseased brain. Astrocyte excitability [which
is based on oscillations in intracellular Ca2+ concentration
([Ca2+]i)] elicits effects in the healthy and diseased brain (Halassa
et al., 2007; Kuchibhotla et al., 2009), and requires sophis-
ticated imaging modalities to elucidate its functional impact.
Neurotransmitter release by neurons leads to elevation of astro-
cyte [Ca2+]i upon binding to receptors on peri-synaptic astro-
cytic membranes, and consequent activation of Phospholipase C.
Spontaneous excitation can also occur. Such elevations in [Ca2+]i
result in astrocytic signaling to neurons, due to the release of
gliotransmitters such as glutamate and D-serine (Araque et al.,
2001; Fellin et al., 2004; Henneberger et al., 2010), and to other
astrocytes.
Calcium oscillations and waves are typically investigated using
chemical calcium indicators. Upon calcium chelation, the spec-
tral properties of such dyes are altered such that they provide
a fluorescent read-out for [Ca2+]i (Tsien, 1988). A cell perme-
able acetoxymethyl (AM) ester form of the indicator dye is often
used. Once inside the cell, the AM bond is cleaved by endogenous
esterases and the dye is trapped within the cell. Using bulk load-
ing techniques all cells will take up the dye. However, by using
astrocyte marker dyes, such as SR101, astrocytes can be identified
(Nimmerjahn et al., 2004). More recently, genetically encoded
molecules have been developed (Miyawaki et al., 1997), which
confer the advantage of being targetable to a specific cell type or
subcellular compartment (Shigetomi et al., 2010). This approach
is particularly exciting for in vivo imaging, as the stable expression
of the calcium reporter allows for long term imaging of calcium
signals (Mank et al., 2008). Generally these indicators comprise of
a calcium binding protein fused to a variant of GFP. Upon calcium
binding, a conformational change of the indicator results in either
a change in the fluorescence resonance energy transfer (FRET)
between the flanking GFPs (Miyawaki et al., 1997; Pologruto et al.,
2004) or a fluorescence change in the molecule itself (Nagai et al.,
2001; Nakai et al., 2001; Shigetomi et al., 2010).
Owing to the optical scattering properties of brain tissue, flu-
orescence imaging is degraded with increasing depth below the
brain surface. Light scattering can be decreased by using infra-
red-shifted light, compared to the use of visible wavelengths. As
light of a longer wavelength has less energy per photon, the near-
simultaneous absorption of multiple photons is required in order
to excite a fluorophore, as occurs in multi-photon microscopy.
Although most chemical calcium indicator dyes were originally
developed for single photon microscopy, some (e.g., rhod-2,
Fluo-4) also have sufficient two-photon cross-section.
Historically, two-photon imaging of calcium oscillations and
waves in astrocytes has been limited to slice preparations
(Mulligan and MacVicar, 2004; Tian et al., 2005; Di Castro et al.,
2011). However, translation of the technique into in vivo sys-
tems has recently become possible. For example, Cirillo et al.
have demonstrated calcium signaling in spinal cord astrocytes in
response to sensory stimulation (Cirillo et al., 2012). Similarly,
whisker stimulation was shown to elicit astrocyte responses in
the barrel cortex (Tian et al., 2006; Wang et al., 2006). With
regards to astrocyte calcium signaling in the diseased brain, ele-
vated signaling has been observed in status epilepticus (Ding
et al., 2007) and has also been demonstrated in the ischemic
penumbra following stroke, where such increased signaling has
been linked to increased neuronal damage (Ding et al., 2009). To
date, application of calcium signaling imaging in CNS tumors,
has been restricted to in vitro preparations of glioma cells
(Charles et al., 1992; Yamasaki et al., 1994) or astrocyte and
glioma cell co-cultures (Zhang et al., 1999). The latter, gap-
junction dependent, interaction has been shown to be necessary
for glioma invasion (Oliveira et al., 2005). Mediators of inflam-
mation have also been shown to modulate astrocyte calcium
signaling in vitro (Hamby et al., 2012) and, hence, one would
anticipate alterations in signaling in the tumor microenviron-
ment that could be probed in vivo using the novel methodologies
outlined above.
MAGNETIC RESONANCE IMAGING
Magnetic resonance imaging (MRI) provides a powerful tool
for imaging soft tissue contrast in the brain. As discussed,
changes in astrocytic morphology accompany astrogliosis, and
there have been attempts to image these changes with MRI. In
both an Endothelin-1 induced ischemia rat model and an NMDA-
induced model of cytotoxicity, T1 relaxation times have been
shown to increase independent of changes in cerebral blood flow.
The observed T1 hypointensities were seen in areas correlating
to astrocyte activation and were reduced upon administration of
arundic acid (Sibson et al., 2008), a selective inhibitor of astrocyte
activation (Tateishi et al., 2002).
Other MRI parameters have been proposed to visualize astro-
cyte activation. Diffusion tensor imaging (DTI) facilitates obser-
vation of tissue microstructure, by both the rate and direction of
water proton diffusion through a given area. By modeling diffu-
sion information in a different manner, accounting for diffusion
kurtosis (DK), it has been proposed that subtle heterogeneity
of tissue can be further characterized. The work of Zhuo et al.
suggests that changes in DK can be correlated with astrocyte
activation and, thus, DK imaging could be used as a tool for
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investigating traumatic brain injury (Zhuo et al., 2012). Both this
modality and the changes in T1 relaxation described above are
still under review with regards to imaging tumor-induced glio-
sis. The resolution of MRI may not allow gliotic regions to be
distinguished from the neoplasm itself, however, both of these
techniques could hold potential as surrogate markers for clinical
tumor detection.
Astrocytes are highly metabolically active, and multiple
metabolic changes also accompany astrogliosis. For example,
increased antioxidant activity is observed upon CNS insult; IL-1β
signaling leads to the expression of cerruloplasmin, which buffers
free copper ions and oxidizes ferrous iron (Kuhlow et al., 2003).
Altered metabolic activity is a further feature of astrogliosis; in a
ciliary neurotrophic factor (CNTF) induced model of astroglio-
sis, fatty acid oxidation and ketone body metabolism is increased,
alongside decreased glycolysis (Escartin et al., 2007), conferring
resistance to metabolic insults.
Under normal conditions, it has been proposed that the ATP
requirements of astrocytes are primarily served by glycolysis
(Pellerin and Magistretti, 1994, 1997), with the end-product,
lactate, extruded into the extracellular space either for uptake
by neurons (Aubert et al., 2005) or clearance from the brain.
However, the TCA cycle and subsequent oxidative phosphory-
lation are also a source of ATP (Serres et al., 2008), and recent
transcriptome analyses of acutely isolated mouse cortical astro-
cytes have demonstrated elevated levels of TCA cycle enzymes as
compared to neurons, combined with high mitochondrial num-
bers in astrocyte foot processes (Lovatt et al., 2007). Whilst,
to date, metabolic changes in reactive astrocytes surrounding
CNS tumors have not been investigated, studies demonstrating
increased glucose utilization by astrocytes in response to TNF,
IL-1β, IL-6, and IFN-γ (Yu et al., 1995; Gavillet et al., 2008;
Belanger et al., 2011), and the synergic activity of TNF and IL-
1β on astrocyte metabolic activity (Gavillet et al., 2008), suggest
that astrocytes in the pro-inflammatory microenvironment will
be in a metabolically hyperactive state. Additionally, the ability of
astrocytes to protect tissue during oxidative stress via the secre-
tion of thiols and enhanced glutamate uptake can be modulated
by the cytokine context (Garg et al., 2009). If this is indeed the
case, a metabolic marker of astrocyte activity, in vivo, could be of
considerable use.
Specificity for astrocyte metabolism, as opposed to neuronal
activity, can be achieved through the differential uptake of cer-
tain metabolic substrates. In particular, acetate is preferentially
taken up by astrocytes over neurons (Waniewski and Martin,
1998) and incorporated into the TCA cycle. 13C magnetic reso-
nance spectroscopy (MRS) studies have demonstrated that it is
possible to detect the transfer of 13C label from [2-13C]acetate
into glutamine within astrocytes. The 13C label is first trans-
ferred to glutamate via the TCA cycle and exchange between the
TCA cycle intermediate α-ketoglutarate (α-KG) and glutamate
(Kanamatsu and Tsukada, 1999; Sibson et al., 2001). Both the
α-KG and glutamate pools in astrocytes are at an extremely low
concentration and, thus, are undetectable by the relatively low
sensitivity 13C MRS. Subsequently, however, the labeled gluta-
mate is converted to glutamine, which is a much larger metabolic
pool (ca. 5–6 mM) and label flux into this pool is detectable by
13C MRS (Sibson et al., 1997). The flux of 13C label from acetate
to glutamine can be converted into absolute rates of astrocytic
TCA cycle (oxidative metabolism) through the use of metabolic
modeling (for review see de Graaf et al., 2011). This 13C MRS
approach has been used in transgenic mouse models of Alexander
disease to show astrocyte dysfunction, with regards to reduced
utilization of acetate for the synthesis of glutamate and glu-
tamine (Meisingset et al., 2010), as well as in human studies. For
instance, human studies in patients with Alzheimer’s disease indi-
cate that [2-13C]acetate can be used to detect gliosis (Sailasuta
et al., 2011), with enhanced metabolism of acetate to 13C bicar-
bonate detected. While MRS has yet to be used to probe stromal
astrocyte metabolism, studies of neoplastic astrocytes in glioma
suggest that intermediates detected with spectroscopy (Doblas
et al., 2012), could be translated into useful imaging tools in PET.
Of relevance here is the use of the PET tracer 18F-acetate which
has been used to demonstrate enhanced glial metabolism in both
a rat stroke model and a glioblastoma model (Marik et al., 2009).
In humans, the PET tracer 11C-acetate has been used for the
detection of gliomas (Liu et al., 2006; Tsuchida et al., 2008). The
use of nuclear imaging to detect gliosis will be further discussed
below.
SPECT AND PET IMAGING
Nuclear imaging, with single photon emission computed tomog-
raphy (SPECT) and positron emission tomography (PET), is
a tool routinely used in the diagnosis of cancer. Radiolabeled
tracers, primarily 18F-deoxyglucose (FDG), are used to detect
tumor growth based on their hyper-metabolism of glucose as
compared to healthy tissue. If astrocytes in and around tumors
are truly hyper-metabolic (see above) then it is likely that
FDG tumor detection may reflect, in part, reactive astrocytosis.
However, imaging the tumors themselves is not the only pos-
sibility for the detection of neoplasms. The use of radiolabeled
compounds to bind to astrocyte specific markers, or indirect
measures of astrocyte activity, are avenues that have been pur-
sued in many CNS diseases, with some agents being translated
into a clinical setting. Whilst SPECT and PET cannot provide
sufficient spatial resolution for probing individual cells, or sub-
populations of cells, these approaches do allow detection of
neuroinflammation, which will facilitate disease diagnosis and
monitoring.
99Tc-HMPAO is a BBB-permeable SPECT imaging agent,
with non-specific uptake by the brain proportional to blood
flow. Retention of the compound is dependent on its intracel-
lular reduction and, thus, the high glutathione concentration
present in astrocytes leads to increased and sustained uptake of
99Tc-HMPAO by astrocytes as compared to neurons (Slosman
et al., 2001). Although not specific for astrocyte activation, reten-
tion of this compound is enhanced in gliotic lesions in dis-
ease states such as dementia and Alzheimer’s disease (Slosman
et al., 2001) and herpes encephalitis (Launes et al., 1995).
Alternatively, 11C-deuterium-L-deprenyl (11C-DED) is an irre-
versible monoamine oxidase B inhibitor. Activated astrocytes
express elevated levels of monoamine oxidase and, consequently,
this agent can be used to detect astrogliosis with PET imag-
ing, as has been demonstrated to date in pathologies such as
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Alzheimer’s (Carter et al., 2012), amyloid lateral sclerosis (ALS)
(Johansson et al., 2007), and Creutzfield–Jakob disease (Engler
et al., 2012).
Probing the increased metabolic activity evident in gliosis at
the mitochondrial level has enabled in vivo imaging of astrocytes
in multiple CNS pathologies, and is a promising tool for monitor-
ing primary and secondary tumor growth. Translocator protein
(TSPO—also known as the peripheral benzodiazepine recep-
tor) is an outer mitochondrial membrane protein (Squires and
Brastrup, 1977), and has multiple functions, including choles-
terol import for steroid synthesis (Hauet et al., 2005), regulation
of mitochondrial metabolism (Hirsch et al., 1989), and apoptosis
(Hirsch et al., 1998). These diverse functions render knock-
out models embryonically lethal (Papadopoulos et al., 1997).
Although the TSPO was originally thought to be exclusively
upregulated on microglia in disease states, recent studies have also
demonstrated increased expression on astrocytes in humans, as
well as in rodent models (Cosenza-Nashat et al., 2009; Lavisse
et al., 2012), as shown in Figure 2. Consequently, interest has
grown in the development and use of radiolabeled compounds
against TSPO for imaging neuroinflammation in diverse CNS
pathologies, such as multiple sclerosis (Harberts et al., 2012),
dementia (Cagnin et al., 2001), Alzheimer’s disease (Versijpt et al.,
2003) and stroke (Gulyas et al., 2012a,b), as reviewed in (Ching
et al., 2012).
In the context of imaging astrocytes in primary brain tumors
(Figure 2), numerous glioma cell lines have been shown to highly
express TSPO (Winkeler et al., 2012), and recent studies in rat
models of glioma (Buck et al., 2011; Tang et al., 2012; Winkeler
et al., 2012) suggest that this approach could be used as a clinical
tool to detect brain tumors. Work in our own group suggests that
radiolabeled anti-TSPO agents can also be used to detect brain
metastases, on the basis of the large area of astrogliosis associ-
ated with these tumors (unpublished work). As discussed with
regard to MRI, these techniques are unlikely to allow differen-
tiation of tumor growth from associated astrogliosis, especially
as TSPO upregulation has been observed in metastatic breast
tumors (Zheng et al., 2011; Batarseh et al., 2012). However, this
approach does hold potential as a surrogate biomarker for the
clinical detection of CNS tumors.
CONCLUSIONS
The role of the microenvironment in tumor progression has
been extensively reported, and an inflammatory response to both
primary and secondary brain tumors is becoming increasingly
apparent. As detailed above, astrocytes are key players in the
FIGURE 2 | Radiolabeled TSPO ligands can be used to image astrocyte
activation in vivo. (A) In a rat model, astrocytes were chronically activated
(GFAP staining, brown) by lentiviral gene transfer of the cytokine ciliary
neurotrophic factor (CNTF). (B) 18F-labeled DPA-714, a TSPO ligand, binding
spatially correlates with areas of astrocyte activation, as observed with
in vivo PET imaging. As adapted from Lavisse et al. (2012). Such TSPO
targeted agents can be used to image TSPO expressing gliomas in
pre-clinical models. (C) A pre-clinical rat model of glioma detected with MRI
(D) 18F-PBR06, a TSPO ligand, binding spatially correlates with glioma
growth, as observed in vivo with PET. As adapted from Buck et al. (2011).
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CNS response to tumor growth, and there have been a flurry
of studies attempting to uncover the role of these glial cells
in disease progression. Many of these studies were conducted
in vitro, and suggest both pro- and anti-tumor effects. However,
the balance of evidence seems to point toward a pro-tumorigenic
role for astrogliosis, with the release of growth factors and matrix
remodeling enzymes. Now that more sophisticated animal mod-
els have been developed, we can begin to understand the complex
role of these cells in vivo. Importantly, functional imaging mea-
surements, via methods such as calcium signaling, will allow
a greater understanding of how astrocytes communicate in the
tumor microenvironment. Multinuclear MRS will yield insights
into tumor metabolism, and potentially elucidate the metabolic
interactions between astrocytes and tumor cells. To elucidate
astrogliotic functions in response to tumor growth, numerous
imaging modalities can be utilized. Not only do these techniques
allow the spatial and temporal profile of gliosis to be visual-
ized and quantified, but they may potentially yield mechanistic
insights through functional imaging and new clinically-relevant
diagnostic approaches.
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